Core Viewpoint - The article highlights the launch of the 13-valent pneumococcal polysaccharide conjugate vaccine, Youpeixin®, developed by CanSino Biologics, which aims to provide better protection against the most prevalent serotypes causing pneumococcal disease in Chinese children [1][2]. Group 1: Vaccine Development and Features - Youpeixin® utilizes an innovative dual carrier strategy, combining a non-toxic mutant of diphtheria toxin (CRM197) as the main carrier and tetanus toxin (TT) as an auxiliary, enhancing immune response against serotypes 19F and 7F [1]. - The vaccine addresses a significant health threat, as pneumococcus is a leading cause of severe diseases in children under five, including meningitis and pneumonia, with a high antibiotic resistance rate of 83.3% in China [1]. Group 2: Production and Quality Control - Youpeixin® adheres to international standards in production and quality control, employing advanced animal-free culture media fermentation processes to minimize potential risks from animal-derived biological factors [2]. - The manufacturing process avoids the addition of phenol, ensuring a safer vaccine preparation [2]. Group 3: Commercialization and Future Plans - CanSino Biologics plans to accelerate the nationwide commercialization of Youpeixin® to ensure widespread access for children [2]. - The company is also developing a comprehensive vaccine product matrix, including vaccines for infants and adolescents, leveraging its strong R&D capabilities [2].